DefinitionThis section has been translated automatically.
Virustatic. Inhibitor of HIV protease.
IndicationThis section has been translated automatically.
Antiretroviral combination therapy for the treatment of HIV-1 infection in patients > 3 years.
Notice!
Consideration of the viral resistance pattern and pretreatment of the patient especially with other protease inhibitors!You might also be interested in
Dosage and method of useThis section has been translated automatically.
- Pat. > 13 y.: 3 times/day 750 mg or 2 times/day 1250 mg p.o. (to be taken with meals).
- Pat. 3-13 yrs. 3 times/day 25-30 mg/kg bw or twice/day 50-55 mg/kg bw p.o.
Undesirable effectsThis section has been translated automatically.
Gastrointestinal symptoms such as nausea (5% of patients), diarrhea (20-30%), cutaneous NW (3-5% of patients) such as erythema, erythema exudativum multiforme, erythema nodosum. Rarely gynecomastia.
InteractionsThis section has been translated automatically.
Simultaneous administration of Nelfinavir and strong CYP 3A inhibitors such as ketoconazole, leads to an increase in the level of action of Nelfinavir.
ContraindicationThis section has been translated automatically.
Patient with severe liver and kidney dysfunction (e.g. WHO group III-IV), children < 3 years. Comedication with rifampicin or CYP3A4 substrates such as terfenadine, St. John's wort, cisapride, pimozide, antidepressants (e.g. diazepam, midazolam, flurazepam) ergotamine derivatives, astemizole, etc.
PreparationsThis section has been translated automatically.
Viracept
Prof. Dr. med. Peter Altmeyer